Why the study?
Does kidney function affect the use of and adherence to cardiovascular medications after myocardial infarction?
Does kidney function affect the use of and adherence to cardiovascular medications after myocardial infarction?
Differences in cardiovascular medication use and adherence after MI across levels of kidney function are unlikely to explain the observed differences in long-term outcomes.
Medication use/adherence differences unlikely explain worse post-MI outcomes by kidney function; leaves open alternative mechanisms for study.
With the exception of lower ACEI/ARB use in patients with CKD, we found no differences between patients with CKD and with no CKD in their use of and adherence to these cardiovascular medications after MI. Patients with ESRD experienced lower use of ACEI/ARB and statins and lower adherence to BB regimens. Postulated differences in medication use after MI across levels of kidney function are unlikely to explain the observed differences in long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Winkelmayer et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: